Alberto Posabella1, Philipp Köhn1, Alexandros Lalos1, Alexander Wilhelm1, Robert Mechera1, Savas Soysal1, Simone Muenst2, Uwe Güth3,4, Sylvia Stadlmann4,5, Luigi Terracciano2, Raoul A Droeser6, Jasmin Zeindler1, Gad Singer4,5. 1. University Center for Gastrointestinal and Liver Diseases (Clarunis), University of Basel, Spitalstrasse 21, 4031, Basel, Switzerland. 2. Institute of Pathology, University Hospital Basel, Schönbeinstrasse 40, 4031, Basel, Switzerland. 3. Brustzentrum Zürich, Seefeldstrasse 214, 8008, Zurich, Switzerland. 4. Department of Gynecology and Obstetrics, University Hospital Basel, Spitalstrasse 21, 4031, Basel, Switzerland. 5. Institute of Pathology, Kantonsspital Baden AG, Im Ergel 1, 5404, Baden, Switzerland. 6. University Center for Gastrointestinal and Liver Diseases (Clarunis), University of Basel, Spitalstrasse 21, 4031, Basel, Switzerland. RaoulAndre.Droeser@clarunis.ch.
Abstract
PURPOSE: Ovarian carcinoma (OC) is the most lethal female genital cancer. After a primary curative surgical approach followed by chemotherapy, a fraction of the patients recur with chemoresistant disease. Data indicate a favorable therapeutic effect of tumor-infiltrating neutrophils (TIN) in OC. Our aim was to investigate the prognostic role of CD66b expression, corresponding to neutrophilic infiltration for recurrence-free survival (RFS) and overall survival (OS) in patients with OC. METHODS: A collective of 47 primary serous ovarian carcinoma and their matching recurrences were processed and stained with CD66b using immunohistochemistry. Tumors from patients with RFS of more than 6 months were defined as chemosensitive. Statistical analysis of CD66b expression was performed to assess the clinical endpoints. RESULTS: High density of CD66b expressing neutrophils in primary carcinoma was associated with chemosensitivity (p = 0.014) and longer RFS (p = 0.001). Univariate analysis identified high density of CD66b expressing neutrophils as a predictor for favorable RFS (HR 0.41, 95% CI 0.22-0.76, p < 0.005). Residual disease > 2 cm (HR 3.67, 95% CI 1.62-8.31, p < 0.002) and higher number of chemotherapy cycles (HR 1.28, 95% CI 1.05-1.55, p < 0.013) were associated with worse RFS. Multivariate analysis showed that high density of CD66b expressing neutrophils (HR 0.22, 95% CI 0.10-0.48, p < 0.001) and residual disease > 2 cm (HR 3.69, 95% CI 1.43-9.53, p < 0.007) were independent predictors of RFS but had no impact on OS. CONCLUSION: High CD66b neutrophil density in primary high-grade OC predicts good response to initial chemotherapy and longer recurrence-free survival independent of known risk factors.
PURPOSE:Ovarian carcinoma (OC) is the most lethal female genital cancer. After a primary curative surgical approach followed by chemotherapy, a fraction of the patients recur with chemoresistant disease. Data indicate a favorable therapeutic effect of tumor-infiltrating neutrophils (TIN) in OC. Our aim was to investigate the prognostic role of CD66b expression, corresponding to neutrophilic infiltration for recurrence-free survival (RFS) and overall survival (OS) in patients with OC. METHODS: A collective of 47 primary serous ovarian carcinoma and their matching recurrences were processed and stained with CD66b using immunohistochemistry. Tumors from patients with RFS of more than 6 months were defined as chemosensitive. Statistical analysis of CD66b expression was performed to assess the clinical endpoints. RESULTS: High density of CD66b expressing neutrophils in primary carcinoma was associated with chemosensitivity (p = 0.014) and longer RFS (p = 0.001). Univariate analysis identified high density of CD66b expressing neutrophils as a predictor for favorable RFS (HR 0.41, 95% CI 0.22-0.76, p < 0.005). Residual disease > 2 cm (HR 3.67, 95% CI 1.62-8.31, p < 0.002) and higher number of chemotherapy cycles (HR 1.28, 95% CI 1.05-1.55, p < 0.013) were associated with worse RFS. Multivariate analysis showed that high density of CD66b expressing neutrophils (HR 0.22, 95% CI 0.10-0.48, p < 0.001) and residual disease > 2 cm (HR 3.69, 95% CI 1.43-9.53, p < 0.007) were independent predictors of RFS but had no impact on OS. CONCLUSION: High CD66b neutrophil density in primary high-grade OC predicts good response to initial chemotherapy and longer recurrence-free survival independent of known risk factors.
Entities:
Keywords:
CD66b; Chemotherapy response; High-grade ovarian cancer; Predictive role of tumor-infiltrating neutrophils
Authors: Arnoud J Templeton; Mairéad G McNamara; Boštjan Šeruga; Francisco E Vera-Badillo; Priya Aneja; Alberto Ocaña; Raya Leibowitz-Amit; Guru Sonpavde; Jennifer J Knox; Ben Tran; Ian F Tannock; Eitan Amir Journal: J Natl Cancer Inst Date: 2014-05-29 Impact factor: 13.506
Authors: Raoul A Droeser; Robert Mechera; Silvio Däster; Benjamin Weixler; Marko Kraljević; Tarik Delko; Uwe Güth; Sylvia Stadlmann; Luigi Terracciano; Gad Singer Journal: BMC Cancer Date: 2016-08-17 Impact factor: 4.430
Authors: O Abu-Shawer; M Abu-Shawer; N Hirmas; A Alhouri; A Massad; B Alsibai; H Sultan; H Hammo; M Souleiman; Y Shebli; M Al-Hussaini Journal: BMC Cancer Date: 2019-02-12 Impact factor: 4.430
Authors: Vittorio Branchi; Benedict Jürgensen; Laura Esser; Maria Gonzalez-Carmona; Tobias J Weismüller; Christian P Strassburg; Jonas Henn; Alexander Semaan; Philipp Lingohr; Steffen Manekeller; Glen Kristiansen; Jörg C Kalff; Marieta I Toma; Hanno Matthaei Journal: J Pers Med Date: 2021-03-23